Company intelligence / Profile preview

KIYATEC

Greenville, South Carolina, United Stateskiyatec.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

KIYATEC has demonstrated strong clinical correlation between its ex vivo functional assays and patient outcomes, particularly in high-grade glioma. Its platforms are used both as a commercial diagnostic service and as a preclinical tool for pharma partners to de-risk oncology assets by predicting therapeutic efficacy using live patient-derived tumor cells.

Therapeutic areas: Oncology
Modalities: Device (diagnostic platform)Ex vivo 3D cell culture technologyFunctional precision oncology assay (service-based)
Industry: Drug Discovery Services

Partnerships

AstraZeneca – multifaceted research agreement to use KIYA-Predict platform for preclinical asset evaluation and translational oncology data generation.

Beyond the preview

Go deeper on KIYATEC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIYATEC.

Explore the full profile